Tumor associated inflammation is one of important predictors of response to immune checkpoint blockade. Understanding molecular processes that regulate tumor inflammation is key to improve the efficacy of checkpoint blockade. Established mechanisms that underlie therapy response and resistance have centered on anti-tumor T cell responses. We show that tumor-associated B cells are vital to T cell functions. They promote recruitment of CD8+ T cells through plasmablast-like cells with expression of pro-and anti-inflammatory factors. Plasmablast-like cells are associated with improved survival of patients with metastatic melanoma and their response to checkpoint blockade. Plasmablast-like B cells express chemokines for T cell-attraction. Depletion of tumor-associated B cells by anti-CD20 immunotherapy of metastatic melanoma patients causes a remarkable decrease in tumor CD8+ T cells. These findings indicate that tumor-associated B cells orchestrate and sustain tumor inflammation, recruit CD8+ T effector cells and are key to therapeutic response and patients' overall survival. 2
Introduction
Cancers such as melanoma, lung, and kidney cancer often present with an inflamed but immunosuppressive tumor microenvironment (TME). Immune checkpoint blocking (ICB) antibodies have significantly improved cancer therapy by overcoming inhibition of T cell effector functions. Yet, a considerable number of patients does not benefit from ICB therapy 1 . It is therefore key to understand the mechanisms that regulate inflammation within the TME to develop novel therapies and improve patient survival. B cells promote both acute immune-associated inflammation for protection against foreign pathogens as well as chronic inflammation in autoimmune diseases and persistent infection. Mouse cancer models show that tumor-associated B cells (TAB) promote tumor inflammation 2,3 but may also inhibit anti-tumor T cell-dependent therapy responses [4] [5] [6] [7] . The immuno-inhibitory function of TAB in these models resembles that of regulatory B cells (Breg), which are an established source of inhibitory cytokines such as IL-10 and TGF-b (reviewed in 8 ). In human cancer, Breg were described by either phenotyping, direct detection of immunoinhibitory cytokines or surface molecules, and/or immunosuppressive function 4, [9] [10] [11] [12] [13] .
Often Breg frequencies increase with tumor progression and are enriched in tumors compared to peripheral blood or adjacent normal tissue. Increased IL-10 + B cell numbers can also be accompanied by increased numbers of CD4 + CD25 +/high CD127 low/and Foxp3 + Tregs in tumor tissues 10, 12, 14, 15 which were independently associated with tumor progression or reduced patient survival.
In human melanoma, up to 33% of the immune cells can be TAB 16, 17 and phenotypic analysis has revealed CD20+ TAB (reviewed in 18 ) and CD138 + or IgA + CD138 + plasma cells 17, 19 .
Conclusions about their impact on disease progression and outcome are inconsistent. So far, no data exist for TAB functions in murine models of melanoma highlighting the need for studies in melanoma patients and tumor samples. We recently showed that TAB-derived IGF-1 is a source of acquired drug resistance of human melanoma to mitogen-activated protein kinase (MAPK) inhibitors 16 . Clinical data from our pilot trial and an independent case series indicate objective tumor responses and clinical benefit through B cell-depletion by anti-CD20 antibodies in end-stage therapy-resistant metastatic melanoma patients 16, 20 .
Human melanoma cells foster the generation of TAB with regulatory activity [21] [22] [23] . They provide antigens for prolonged B cell receptor stimulation and release inflammation-modulating cytokines such as IL-1b, IL-6 24 and IL-35 25 . The functional phenotypes of TAB in human melanoma and their impact on inflammation and response to ICB therapy are, however, still unknown.
We therefore systematically characterized the effect of human melanoma cells on autologous B cells in vitro ( Supplementary Figure 1 ). This induced a phenotypic and functional change of B cells towards a plasmablast-like phenotype with expression of pro-and anti-inflammatory molecules. This phenotype could be recapitulated in single-cell (sc) RNA-sequencing (seq) data from metastatic melanoma patients. In this data, plasmablast-like B cells expressed several chemokines attracting immune cells, for example, T cells and macrophages. The increase of this plasmablast-like B cell subpopulation through anti-PD1 therapy led to a marked increase of tumor-associated inflammation and immune cell numbers and predicted survival. Accordingly, the depletion of B cells in metastatic melanoma patients drastically decreased overall inflammation and immune cell numbers in the TME.
Results

Melanoma TAB are composed of multiple phenotypes
We used 7 color multiplex immunostaining (CD20, CD19, CD5, CD27, CD38, CD138, and DAPI) to approximate 6 different TAB-subpopulations ( Figure 1A , Supplementary Figure 2A ) in tissue microarrays composed of cores from 155 human metastatic melanomas (Supplementary Figure 2B ). In total, we observed 1,991 (45%) plasmablast-like TAB ( Figure 1B Figure 2B ). TAB are primarily located at the invasive tumor-stroma margin 16, 17, 26 . This suggests a preferentially contact independent communication between melanoma cells and TAB. 
Human melanoma cells directly induce NFKB activation in TAB through soluble factors
The known release of pro-and anti-inflammatory cytokines from melanoma cells and our multiplex immunostaining results suggest that melanoma cells communicate through soluble factors with TAB. We therefore exposed immortalized peripheral blood-and tumor-derived B cells derived from 4 patients with metastatic melanoma to melanoma-conditioned medium collected from autologous early passage melanoma cells. In a screen for expression of the key immunoregulatory and pro-inflammatory cytokines/molecules PD-L1 and IL-6, all melanoma conditioned media induced a similar up-regulation in matched peripheral blood-and tumor-derived B cells (Supplementary Figure 4A ). We therefore performed subsequent experiments with the melanoma conditioned medium from patient 2 as it induced the most prominent changes.
572 genes/proteins were identified as significantly regulated by melanoma conditioned medium in both, the RNA-seq and proteomics results. Additionally, 974 proteins were found only significantly regulated in the proteomics data and 2,520 genes found only significantly regulated in the RNA-seq data (Benjamini-Hochberg (BH) corrected p-value < 0.05, Supplementary Table   1 ). There was no marked difference between peripheral and tumor-derived B cells ( Figure 2A ).
The estimated fold changes of genes identified as significantly regulated in both approaches showed a high linear correlation (Spearman cor = 0.79, p < 0.01, Supplementary Figure 4B ).
The subsequent pathway analysis (see Methods) showed upregulation of pathways associated with inflammation, immunity, B cell receptor signaling and intracellular signal transduction, and downregulation of pathways associated with cell cycle, cell division, DNA replication, DNA repair, translation, and transcription (Supplementary Table 1 ).
One of the most significantly upregulated pathways was "tumor necrosis factor (TNF) signalling via NFKB. NFKB is a key transcription factor for B cell activation in inflammation and immune response 27 . This pathway includes, among others, CD69, CD80, CD30 (TNFRSF8), and CD137 (4-1BB/TNFRSF9) which were significantly upregulated in our proteomics and transcriptomics data (with CD30 (TNFRSF8) among the top-20 upregulated genes) and are known to be upregulated in B cells upon activation. Even though TNF itself showed no significant differences, TNF alpha induced protein 2 (TNFAIP2) was significantly upregulated as indirect evidence for TNF signalling. In addition, we observed the up-regulation of CD40 signalling genes which also acts via NFKB. Additionally, we found increased phosphorylation of PRKCB which plays a key role in B cell activation by regulating BCR-induced NFKB activation (with no significant differences in transcriptomics or global proteomics analysis). Similarly, we observed an increased phosphorylation of NKAP which is involved in TNF-and IL-1 induced NFKB activation. Therefore, melanoma-derived soluble factors directly induce a signalling pattern in B cells associated with activation in inflammation and immune response.
Melanoma conditioned medium induces a plasmablast-like dominated TAB population
The downregulation of cell cycle associated pathways coincided with a significant, unexpected down-regulation of CD20 (MS4A1, BH adjusted p < 0.01 RNA-seq) and CD19 (BH adjusted p < 0.01 proteomics). This indicates a phenotypic change of B cells. To identify this phenotype, we first used the Reactome functional interaction network 28 and extracted all neighbours of CD19
and their neighbours ( Figure 2B ). While known key developmental phenotype, including reported regulatory B cell markers such as CD147, CD24, CD27, CD25, CD39, CD73, or CD138 together with transcription factors BLIMP-1, XBP-1 were not significantly regulated, 8 downregulated (IRF4, CD71) or not detectable (CD5, TIM1), we found a significant upregulation of CD38 (proteomics, BH adjusted p = 0.01), together with PAX5 (BH adjusted p < 0.01 RNA-seq).
Secondly, 9-color FACS staining showed changes of CD19, CD20, CD24, CD27, CD38
and CD138 consistent with proteomics and RNA-seq results ( Figure 2C ). Immunoglobulin D, M and G expression was unchanged (Supplementary Figure 4C ). The induction of CD38 points towards a plasmablast/-cytoid differentiation. This is counter-regulated by increased PAX5 expression. These findings correlate with the high proportion of plasmablast-like TAB in human melanomas (Supplementary Figure 2B ). Based on these results, we defined a tumor-induced plasmablast-like dominated B cell population (TIPB) signature with the genes CD27, CD38, and PAX5. We used scRNA-seq data from two recent large studies on immune-checkpoint response in melanoma 29, 30 to validate these functional signatures. Since CD19 and CD20 were downregulated in the induction experiments, we compared CD27+CD38+ TIPB with CD19+CD20+ TAB ( Figure 3A , 3B). This resulted in 623 CD19+CD20+ TAB and 814 TIPB (Jerby-Arnon et al. 30 ) and 1,063 CD19+CD20+ TAB and 2,941 TIPB (Sade-Feldman et al. 29 ).
The data scarcity prevented the definition of more fine-grained phenotypes. Only 5% of cells expressing CD27 and CD38 were also expressing CD138 (SDC1) in both datasets. 40 We defined a cell to express a signature if it expressed at least all of the signature's genes minus one with a minimum number of required genes of two and a maximum of four. This analysis showed that the activation, co-stimulation and immune-checkpoint signatures are expressed in TIPB and to a lesser extent in CD19+CD20+ TAB (Fisher-exact test, BH corrected p-value < 0.01 both datasets, activation Jerby-Arnon BH adjusted p = 0.03, Figure 3C ). Both, CD19+CD20+ TAB and TIPB expressed substantial levels of immunosuppressive cytokines such as TGFB1 and IL-10 ( Figure 3D ). Expression of the latter in TIPB could be additionally validated through multiplex immunostaining ( Figure 3E ). Remarkably, TIPB also expressed numerous chemokines including T cell and macrophage chemoattractants XCL1, CCL22 and CSF1 ( Figure 3D ). Together, these results indicate that TIPB are able to regulate inflammation and shape the cellular composition of the human melanoma TME. Figure 5C ) and macrophages (Spearman correlation 0.71, p < 0.01) as estimated by xCell 31 . Established signatures describing the inflammatory TME and possible response to anti-PD1 therapy (tumor inflammatory score 32 , interferon gamma 33 , T-cell exhaustion 34 , and T-cell effector 35 
signatures)
additionally showed a high linear correlation with our TIPB signature (Spearman correlation >= 0.85, BH adjusted p < 0.01, Supplementary Figure 5D ). Finally, high expression (above median) of our TIPB signature was correlated with longer overall survival in the TCGA cohort ( Figure   4A ). These results show, that the TIPB and the predicted functional signatures, are highly associated with T cell abundance and inflammation, and, importantly, are linked with patient outcome.
Anti-PD1 therapy frequently leads to an increase in B cell numbers which should enhance our functional signatures. We used the transcriptomics data by Riaz Figure 4B ). TIPB did not correlate with clinical response (Supplementary Figure 7 ) but high expression of our TIPB signature before therapy (top 25% versus lower 25%) predicted overall survival (Likelihood ratio test p = 0.06, Figure 4C ).
Together, these data validate the clinical importance of the identified TIPB. 
Loss of TAB reduces inflammation in the tumor microenvironment
Finally, we evaluated the loss of TAB in a cohort of patients with metastatic melanoma treated with anti-CD20 antibodies 16, 36 (see Methods, Supplementary Figure 1 ). The dataset consists of 4 patients with pre-and on-therapy samples of established metastases (affected by anti-CD20 therapy, therapeutic setting) and 2 patients with pre-and on-therapy samples, where the metastases developed de-novo in B cell depleted patients on therapy 37 (adjuvant setting).
Principal component analysis of whole tissue RNA-seq showed no systematic difference between the two patient groups ( Figure 5A ).
Next to the expected down-regulation of CD19 and CD20 (MS4A1), all patients showed a consistent, significant down-regulation of CD8A on anti-CD20 therapy (BH adjusted p = 0.02, Supplementary Table 2 ). This was linked to a consistent reduction of CD8+ T-cells (one-sided, paired t-test, BH adjusted p = 0.07, t = 1.74, df = 5) and macrophages (one-sided, paired t-test, BH adjusted p = 0.07, t = 2.17, df = 5, Figure 5B ). A signature consisting of CD4 and FOXP3 to approximate the abundance of FOXP3+ T cells also decreased significantly (one-sided, paired t-test p = 0.05, df = 5, t = 2.03, Figure 5B ).
Anti-CD20 therapy caused a significant downregulation of our TIPB signature and all our functional signatures (one sided, paired t-test, BH adjusted p-value 0.01 -0.04, t = 2.3 -4.8, df = 5, Supplementary Figure 8A ). Published signatures describing the inflammatory TME and possible response to anti-PD1 therapy (tumor inflammatory score 32 , interferon gamma 33 , T-cell exhaustion 34 , and T-cell effector 35 signatures) highly correlated with our TIPB signature (Spearman correlation 0.7 -0.9, BH adjusted p < 0.01, Supplementary Figure 8B ) and showed a significant decrease on anti-CD20 therapy (one-sided, paired t-test, BH adjusted p = 0.01, df = 5, t = 3.11 -5.46, Figure 5D ). These data validate the essential role of TIPB to sustain tumor inflammation and recruit CD8+ T cells and macrophages in human melanoma.
18 We observed TIPB to express many immunostimulatory and -inhibitory cell surface receptors and molecules. Their co-expression characterizes TIPB as a rather unique B cell population. Melanoma-induced stimulatory signatures indicated antibody-independent functions of TIPB, such as antigen presentation, T cell activation and cytokine production with the ability to promote local inflammation as recently shown in multiple sclerosis 41 . TIPB also expressed inhibitory receptors and ligands as well as IL10 and TGFB1 as indicated by scRNA-seq and multiplex immunostaining data. Therefore, TIPB resemble Breg, which directly and indirectly suppress proliferation, anti-tumor activity, and differentiation of several immune cells residing in the TME [42] [43] [44] [45] [46] [47] . The expression of these inhibitory factors in TIPB is in line with previous reports on human CD27 int CD38 + CD138plasmablasts as a major IL-10+ B cell population 44 , human colorectal cancers being highly enriched for IL-10+CD19 lo CD27 hi plasmablasts that can suppress IL-17A + CD4 + T cells 48 and murine IgA + PD-L1 + IL10 + plasmocytes that prevent CD8 + T cell-mediated regression of hepatocellular carcinoma 7 and impede T cell-dependent chemotherapy of castration-resistant prostate cancer 4 . Our data expand these observations by pinpointing the additional expression of inhibitory ligands such as PDCD1/LG2PD-L2,
LGALS9/Galectin-9, and TNFRSF14/HVEM in TIPB. These ligands can stimulate their cognate inhibitory receptors PD1/PDCD1, HAVCR2/TIM-3 and BTLA, which are induced on T cells upon persistent antigen exposure and drive T cell dysfunction. The expression of these inhibitory receptors on TIPB themselves may point to an additional autoregulatory mechanism.
The "tide model" describes expression of co-stimulatory and inhibitory signals as a dynamic system to fine-tune immune responses 49 . Additionally, the "immune set point model"
highlights the often subtle contribution of intrinsic and extrinsic factors that modulate tumor inflammation and tip the balance between immunity and tolerance 38 
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Methods
Data availability
RNA-seq data have been deposited in the ArrayExpress 50 database at EMBL-EBI 
Patient-derived material
Of 10 patients with metastatic melanoma who were treated with the anti-CD20 antibody ofatumumab in a therapeutic setting 16 and TAB, we included one further patient who was considered for but did not undergo anti-CD20 therapy.
In addition, of two patients with metastatic melanoma who were treated with the anti-CD20 antibody rituximab in an adjuvant setting 37 Supplementary Table 3 .
Induction experiments with Melanoma-conditioned medium (MCM)
Immediately after surgical resection, melanoma cells and TAB were collected by mechanical and enzymatic dissociation of metastatic melanoma tissue into single cells (tumor dissociation kit, gentleMACS Dissociator, both Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) as described earlier by us 52, 53 . Peripheral blood samples were collected in BD Vacutainer CPT cell preparation tubes and PBMC prepared according to the manufacturer's instructions.
Melanoma cells grown from these single cell suspensions were frozen after passage 2 and stored in liquid nitrogen. 
Proteomics analysis
Cell lysis and protein digestion
All reagents were of analytical grade and obtained from SIGMA-Aldrich, unless specified otherwise. Cells were lysed in freshly prepared lysis buffer containing 100 mM Tris/HCL pH 7.6, 2 % sodium dodecyl sulfate (SDS), 1 mM sodium vanadate, 1 mM NaF, protease inhibitor (cOmplete Tm EDTA-free) and phosphatase inhibitor (PhosSTOP Tm ) cocktail tablets (both Roche).
Cell extraction and DNA sharing was assisted by sonication and cell debris pelleted by centrifugation at 20.000 x g for 15 min at 20°C. The supernatant was collected and the total protein concentration determined using the BCA protein assay kit (Pierce Biotechnology).
Filter-aided sample preparation (FASP) was performed using Amicon Ultra Centrifugal 30 kDa molecular weight cutoff filters (Millipore) essentially according to the procedure described by 55 . 
Off-line basic pH reversed-phase fractionation
Off-line high-pH reversed phase fractionations was performed essentially according to 56 
Transcriptomics analysis
Library preparation and sequencing
The amount of total RNA was quantified using the Qubit Fluorometric Quantitation system (Life Technologies) and the RNA integrity number (RIN) was determined using the Experion Automated Electrophoresis System (Bio-Rad).
For the co-culture experiments the isolated RNA (1µg) was processed using the SENSE 
Data analysis and statistical information
All statistical tests were performed using R version 3.5.1 58 For quantitation all spectra with >30% interference based on total ion current were discarded.
Isotope impurity correction and normalisation of intensity values was performed using the R Bioconductor package isobar 62 36 . The TPM normalized expression values were downloaded from GEO (GSE91061).
Signature expression levels were estimated using the ssGSEA approach and cell type abundances estimated using xCell (see above).
scRNA-seq from Jerby-Arnon et al. 30 and Sade-Feldman et al. 29 were directly downloaded from GEO as TPM normalized expression values (GSE115978 and GSE120575). Only cells with expression levels for CD19, CD20 (MS4A1), CD27, or CD38 were kept for further analysis. A cell was considered to express a gene as soon as expression values TPM > 0 were observed. t-SNE analysis was performed using the Rtsne package 76 Multiplex IHC staining 4 μm sections from full FFPE blocks that were used to generate the TMA or from control tonsil tissue were utilized for both, the initial establishment of staining conditions for each individual primary antibody (Ab) and the successive optimization of multiplex staining. In a first step, primary Abs against the following antigens were established as single stains initially on human tonsil tissue and thereafter on metastatic human melanoma tumors: CD19, CD20, CD5, CD27, CD38, CD138, CD8, FoxP3 and IL10 (Supplementary Table 4 ).
In a second step, multiplex immunostains were established essentially as described 77, 78 .
Random integration of sequential Abs within a multiplex panel may lead to imbalanced signals, incomplete staining through interference with previously applied tyramide signal amplification (TSA), disruption of epitopes, and removal of TSA fluorophores because of repetitive antigen-retrievals at high temperature 77, 78 . Therefore, each Ab was tested individually for its optimal position in the sequence of multiplex staining to minimize interference with previous Ab-TSA complexes or by alteration of epitopes.
For multiplex immunostains, 4 μm sections were deparaffinized and antigen retrieval was performed in heated citrate buffer (pH 6.0) and/or Tris-EDTA buffer (pH 9) for 30 min.
Thereafter, sections were fixed with 7.5% neutralized formaldehyde (SAV Liquid Production GmbH). Each section was subjected to 6 successive rounds of Ab staining, each consisting of protein blocking with 20% normal goat serum (Dako) in PBS, incubation with primary Abs, biotinylated anti-mouse/rabbit secondary antibodies and Streptavidin-HRP (Dako), followed by TSA visualization with fluorophores Opal 520, Opal 540, Opal 570, Opal 620, Opal 650, and
Opal 690 (PerkinElmer) diluted in 1X Plus Amplification Diluent (PerkinElmer), Ab-TSA complex-"stripping" in heated citrate buffer (pH 6.0) and/or Tris-EDTA buffer (pH 9) for 30 min and fixation with 7.5% neutralized formaldehyde. Thereafter, nuclei were counterstained with DAPI (PerkinElmer) and sections mounted with PermaFluor fluorescence mounting medium (Thermo Fisher Scientific).
Respective stainings without primary antibodies were used as a negative control. Along with tissue arrays, serial sections of melanoma specimens and normal controls were stained to assess reproducibility. At equal Ab-concentrations, TSA-based visualization is expected to yield a higher number of positive cells as compared to conventional immunofluorescence. We therefore established TSA-based visualization of primary Abs on control tonsil tissue, the golden standard for lymphocyte antigen detection in pathology, and performed a comparison for each Ab to validated staining patterns in human tonsil (as to the Human Protein Atlas 79 , available from www.proteinatlas.org ). Thereafter, we balanced the signal through dilution of the primary Abs to obtain staining levels and cell frequencies comparable to conventional immunofluorescence staining. The dilution of the CD19 antibody was optimized to allowing for the detection of CD19 low plasma cell-like cells as compared to patterns and frequencies obtained by CD138+ pooled IgA/IgG+ stainings on human tonsil and melanoma 17, 19 . In multiplex stainings, single primary Ab stainings were run in parallel to control for false positive results through incomplete Ab-TSA complex-"stripping" and false negative results through antigen masking (by incubation with multiple primary Abs, "umbrella-effect"). Spillover effects were controlled for anti-CD20-Ab stainings on tonsil with different Opal fluorophores by signal detection in adjacent components/channels and thereafter for exposure time settings upon acquisition of multiplex-stained tissue sections.
Tissue imaging, spectral unmixing and phenotyping
Multiplexed slides were scanned on a Vectra Multispectral Imaging System version 2 (Perkin Elmer) as described 77, 78 . Briefly, a spectral library from spectral peaks emitted by each fluorophore from single stained slides was created with the inform Advanced Image Analysis software (InForm 2.4, PerkinElmer) and used for spectral unmixing of multispectral images allowing for identification of all markers of interest. Autofluorescence was determined on an unstained representative study sample. To subtype TAB in TMA, cells were phenotyped as (i) CD19 + CD20 -CD38 + CD138plasmablast-like, CD19 + CD20 -CD138 + plasma cell-like, CD19 + CD20 + CD38 -CD138memory B cell-like, CD20 + CD38 + CD138 -CD5germinal center B cell-like, CD19 + CD20 -CD38 -CD138 -CD27 + activated B cell-like, CD20 + CD19 -CD138 -CD5 + transitional cell-like TAB and (ii) other cells. The staining protocol has been optimized for detection of CD19. Though CD19 low plasma cell-like cells could be detected at significant numbers, they may still be underrepresented in our staining data. The same may also be true for the detection of activated B cell-like cells, as expression of CD27 has been reported to be downregulated on TAB 40, 80 . Human melanoma cells can express CD38 81 and we observed some cores with slight CD38 immunoreactivity of melanoma cells. In these cores tumor cell areas were excluded with the "exclusion area tool" of InForm. After adaptive cell segmentation, a selection of around 25 representative original multispectral images was used to set cut-off values for each fluorophore/antibody staining. All phenotyping and subsequent quantifications were performed blinded to the sample identity.
